Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 3Thrombocythemia, Essential 1Primary Myelofibrosis 1Preleukemia 1Precancerous Conditions 1Peripheral Nervous System Neoplasms 1Neurofibrosarcoma 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Hematologic Diseases 1Bone Marrow Diseases 1

Interventions

Doxorubicin 17Ifosfamide 12Radiotherapy 8pazopanib 5selinexor 4pembrolizumab 4Filgrastim 4pegfilgrastim 3Sirolimus 3Nivolumab 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3Etoposide 3AZD 6244 3fludarabine phosphate 2brostallicin 2X-Rays 2Trabectedin 2Specimen Handling 2Sorafenib 2Radiation Dose Hypofractionation 2Radiation 2Diathermy 2Chemotherapy, Adjuvant 2Biopsy 2thymoglobulin 1temsirolimus 1tazemetostat 1sotigalimab 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibrosarcoma × CPI-0610 × Clear all
NCT02986919 2018-09-11

Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors

University of Texas Southwestern Medical Center

Phase 2 Withdrawn
Sarcoma

Peripheral Nervous System Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡